Zimmer Biomet Holdings, Inc. (ZBH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Ivan Tornos - President, CEO & Chairman of the Bo...
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some ...
Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA
I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could ...
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs Acquisition expected to be neutral to adjusted earnings...
We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
Ivan Tornos, Zimmer Biomet CEO, joins 'Closing Bell Overtime' from the CNBC CEO Council Summit to talk navigating a changing political landscape, partnering with Arnold Schwarzenegger and more.
Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds
Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and ...
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty
Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28 , currency volatility, and p...
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som...
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.
Zimmer Biomet: Adding To The Growth Profile
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, b...
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - P...
Unveiling Zimmer (ZBH) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q...
Zimmer Biomet Set to Report Q4 Earnings: What's in Store?
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with ...
Reasons to Retain ZBH Stock in Your Portfolio for Now
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
Related Companies